Sclerostin

Mechanism of Action

• Binds the first beta-propeller domain of LRP5/6 via a loop-2 cysteine-knot motif, preventing Wnt-mediated Frizzled/LRP5-6 complex formation
• Loss of Wnt/beta-catenin signaling in osteoblasts: reduces proliferation, differentiation, and collagen/osteocalcin synthesis
• Osteocyte-produced sclerostin is the primary mechanosensor: mechanical loading suppresses SOST expression, allowing Wnt-driven bone formation in loaded regions
• Increases RANKL/OPG ratio in osteoblasts/osteocytes, secondarily promoting osteoclast-mediated bone resorption
• Inhibited by PTH/PTHrP via cAMP/PKA pathway: PTH therapy suppresses sclerostin expression, partially explaining PTH anabolic effects on bone

Research Findings

• Sclerosteosis (SOST null) and van Buchem disease (SOST regulatory deletion) patients have massively increased bone density without other health problems, establishing sclerostin as purely bone-regulatory
• Romosozumab (anti-sclerostin antibody): Phase III FRAME trial showed significant reduction in vertebral and non-vertebral fractures vs placebo in postmenopausal women
• Romosozumab has dual action: increases bone formation markers (P1NP) and decreases bone resorption markers (CTX) simultaneously, unique among osteoporosis drugs
• Sclerostin elevated in diabetes, chronic kidney disease, and corticosteroid therapy, contributing to secondary osteoporosis in these conditions
• Recombinant sclerostin used in research to inhibit bone formation in vitro and validate anti-sclerostin drug targets

Research Protocols

• Recombinant sclerostin: 1-100 nM to inhibit Wnt3a-stimulated osteoblast differentiation (ALP, osteocalcin) in MC3T3-E1 cells
• In vivo bone research: 100-300 mcg/kg SC or IV recombinant sclerostin in rats to suppress bone formation markers
• Romosozumab (Evenity): 210 mg SC monthly for 12 months in postmenopausal osteoporosis (FDA-approved regimen)
• LRP5/6 binding assay: 125I-sclerostin displacement at 1-100 nM; Kd ~1-5 nM for LRP6 beta-propeller

Interactions

• Romosozumab (Evenity): anti-sclerostin antibody, FDA-approved; blocks sclerostin-LRP5/6 interaction
• PTH/teriparatide: downregulates sclerostin expression; anabolic bone effects partially mediated by sclerostin suppression
• DKK1: another LRP5/6 antagonist; sclerostin and DKK1 act cooperatively to suppress bone formation

Safety Profile

Recombinant sclerostin is a research tool. Anti-sclerostin therapy (romosozumab) clinical data: slightly increased cardiovascular events in ARCH trial vs alendronate (not vs placebo); FDA label carries cardiovascular warning. Contraindicated within 12 months of MI or stroke.

Legal & Regulatory

Sclerostin itself is a research reagent. Romosozumab (Evenity) FDA-approved 2019 for postmenopausal osteoporosis at high fracture risk.